Positive Phase 2a Findings for Vortosiran: A Breakthrough in siRNA-mediated FXI Inhibition#China#Shanghai#Ribo_Life_Science#Vortosiran#Fakelixir
Positive Phase 2a Findings for Vortosiran: A Breakthrough in siRNA-mediated FXI Inhibition
Suzhou Ribo Life Science announces promising Phase 2a data for Vortosiran, a significant siRNA therapy targeting FXI in coronary artery disease patients.
third-news.com
July 23, 2026 at 12:12 AM
Positive Phase 2a Findings for Vortosiran: A Breakthrough in siRNA-mediated FXI Inhibition#China#Shanghai#Ribo_Life_Science#Vortosiran#Fakelixir